CS12192 is a highly selective JAK3 kinase inhibitor independently developed by Microchip, which has been granted global patent of compound invention, and partially inhibits JAK1 and TBK1 kinases

Completed preclinical studies have shown that CS12192 in rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus (sle) and autoimmune diseases such as psoriasis model and graft versus host disease (GVHD) model which has obvious efficacy activity, on the part of the model shows that different from other JAK kinase inhibitor of differentiation pharmacokinetics characteristics. Compared with the existing JAK kinase inhibitors, CS12192 can not only effectively inhibit inflammation mediated by overactivation of immune cells, but also reduce tissue invasion of immune cells by inhibiting TBK1, bringing better efficacy and safety, which is expected to provide a new differentiated treatment option for the clinical treatment of autoimmune related diseases.